福瑞达(600223) - 2025 Q3 - 季度财报

Financial Performance - Total revenue for Q3 2025 was CNY 807,271,233, a decrease of 7.97% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 33,780,841.2, down 23.07% year-on-year[3] - The net profit after deducting non-recurring gains and losses decreased by 34.87% to CNY 25,579,567.5, primarily due to the product iteration phase of core cosmetics and reduced online traffic[7] - The basic earnings per share for the quarter was CNY 0.03, a decline of 26.42% compared to the same period last year[3] - Total operating revenue for the first three quarters of 2025 was CNY 2,596,812,901.60, a decrease of 7.4% compared to CNY 2,802,563,091.30 in the same period of 2024[18] - Net profit for the first three quarters of 2025 was CNY 178,355,243.27, a decline of 15.0% from CNY 209,546,814.29 in 2024[19] - Total comprehensive income for the first three quarters of 2025 was CNY 178.36 million, a decrease of 14.87% compared to CNY 209.55 million in the same period of 2024[20] - Basic and diluted earnings per share for the first three quarters of 2025 were CNY 0.14, down from CNY 0.17 in 2024[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,831,204,120, a decrease of 2.82% from the end of the previous year[3] - As of September 30, 2025, total assets amounted to CNY 5.831 billion, while net assets attributable to the parent company were CNY 4.187 billion[11] - The company's total liabilities decreased from CNY 4.143 billion at the end of 2024 to CNY 3.968 billion as of September 30, 2025[15] - The company's total liabilities as of September 30, 2025, were CNY 942,214,014.59, a decrease of 22.2% from CNY 1,211,965,199.14 at the end of 2024[17] - Total equity attributable to shareholders as of September 30, 2025, was CNY 4,186,812,185.70, an increase of 2.0% from CNY 4,104,899,060.85 at the end of 2024[17] Cash Flow - Cash flow from operating activities for the year-to-date period decreased by 37.00% due to reduced sales receipts[7] - Net cash flow from operating activities for the first three quarters of 2025 was CNY 38.67 million, down 37.00% from CNY 61.38 million in 2024[21] - Cash inflow from operating activities totaled CNY 2.80 billion in 2025, a decrease of 4.05% from CNY 2.92 billion in 2024[21] - Cash outflow from operating activities was CNY 2.76 billion in 2025, down 3.34% from CNY 2.85 billion in 2024[21] - Net cash flow from investing activities was -CNY 29.76 million in 2025, a significant decline from CNY 3.03 billion in 2024[21] - Cash inflow from financing activities was CNY 248.58 million in 2025, an increase from CNY 202.21 million in 2024[21] - Net cash flow from financing activities was -CNY 180.52 million in 2025, an improvement from -CNY 1.96 billion in 2024[21] - The ending cash and cash equivalents balance for the first three quarters of 2025 was CNY 2.63 billion, a decrease from CNY 2.83 billion in 2024[21] Shareholder Information - The company reported a total of 44,533 common shareholders at the end of the reporting period[9] - The largest shareholder, Shandong Commercial Group Co., Ltd., holds 51.6% of the shares, amounting to 524,739,200 shares[9] Segment Performance - For the first nine months of 2025, the company achieved operating revenue of CNY 2.597 billion and a net profit attributable to the parent company of CNY 142 million[11] - The cosmetics segment reported revenue of CNY 1.569 billion, a year-on-year decline of 8.17%, with a gross margin of 61.24%[11] - The Yilian brand generated sales of CNY 786 million, a year-on-year increase of 19.50%, while the spray product line achieved sales of CNY 664 million, up 28%[11] - The pharmaceutical segment's revenue was CNY 305 million, down 17.46%, with a gross margin of 52.27%[12] - The raw materials and additives segment saw revenue of CNY 276 million, an increase of 11.19%, with a gross margin of 40.26%[13] Research and Development - Research and development expenses for the first three quarters of 2025 were CNY 116,058,297.86, up 11.7% from CNY 103,797,009.10 in 2024[18] - The company developed over 200 new customers across hospital and OTC channels during the reporting period[12] - The company launched 7 new health products during the third quarter, including Red Ginseng and Ejiao Peptide drinks[13] Financial Standards - The company has not adopted new accounting standards for the year 2025[22]